Lyra Therapeutics (LYRA) Share-based Compensation (2019 - 2025)
Quarterly Share-based Compensation fell 71.02% to $562000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 65.23% year-over-year, with the annual reading at $2.3 million for FY2025, 65.23% down from the prior year.
Lyra Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $562000.0 for Q4 2025.
- Share-based Compensation came in at $562000.0 for Q4 2025, up from $34000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.2 million in Q1 2024 to a low of $34000.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $1.1 million (2022), against an average of $1.2 million.
- Year-over-year, Share-based Compensation soared 347.01% in 2021 and then plummeted 97.72% in 2025.
- Lyra Therapeutics' Share-based Compensation stood at $782000.0 in 2021, then surged by 124.68% to $1.8 million in 2022, then decreased by 15.65% to $1.5 million in 2023, then skyrocketed by 30.84% to $1.9 million in 2024, then plummeted by 71.02% to $562000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Share-based Compensation are $562000.0 (Q4 2025), $34000.0 (Q3 2025), and $914000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Lyra Therapeutics | - | - | - | 562,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 562,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Dec 31, 2024 | 1.94 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.74 Mn |
| Sep 30, 2022 | 1.74 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 844,000.00 |
| Mar 31, 2022 | 844,000.00 |
| Dec 31, 2021 | 782,000.00 |
| Dec 31, 2021 | 782,000.00 |
| Sep 30, 2021 | 733,000.00 |
| Sep 30, 2021 | 733,000.00 |
| Jun 30, 2021 | 656,000.00 |
| Jun 30, 2021 | 656,000.00 |
| Mar 31, 2021 | 599,000.00 |
| Mar 31, 2021 | 599,000.00 |
| Dec 31, 2020 | 592,000.00 |
| Dec 31, 2020 | 592,000.00 |
| Sep 30, 2020 | 468,000.00 |
| Sep 30, 2020 | 468,000.00 |
| Jun 30, 2020 | 619,000.00 |
| Jun 30, 2020 | 619,000.00 |
| Mar 31, 2020 | 134,000.00 |
| Mar 31, 2020 | 134,000.00 |
| Dec 31, 2019 | 103,000.00 |
| Dec 31, 2019 | 103,000.00 |
| Sep 30, 2019 | 49,000.00 |
| Sep 30, 2019 | 49,000.00 |
| Jun 30, 2019 | 44,000.00 |
| Jun 30, 2019 | 44,000.00 |
| Mar 31, 2019 | 48,000.00 |
| Mar 31, 2019 | 48,000.00 |